adequate trials of nonsteroidal antiinflammatory drugs for pain control
An analgesic should not be considered a failure unless it has been given an adequate trial. For non-cancer-related pain, 2 weeks of treatment with a maximum scheduled dose constitutes an adequate trial. For cancer-associated pain, a 1-week duration of continuous dosing is considered sufficient. However, ketorolac is not recommended for more than 5 days’ duration because of the risk of serious GI and other side effects.
